Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer: A multi-institution study.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14504-e14504
Author(s):  
James Joseph Biagi ◽  
Ronald L. Burkes ◽  
Christine B. Brezden ◽  
Kevin M. Zbuk ◽  
Brandon Matthew Meyers ◽  
...  
2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 6541-6541
Author(s):  
Ketan Ghate ◽  
Ronald L. Burkes ◽  
Christine B. Brezden ◽  
Kevin M. Zbuk ◽  
Brandon Matthew Meyers ◽  
...  

2014 ◽  
Vol 25 ◽  
pp. iv198
Author(s):  
J. Biagi ◽  
R. Burkes ◽  
C. Brezden-Masley ◽  
K. Zbuk ◽  
B. Meyers ◽  
...  

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 75-75
Author(s):  
Teresa V. Brown ◽  
Kristen Donohue ◽  
Sondra Patella ◽  
Viktor Y. Dombrovskiy ◽  
Rebecca Anne Moss ◽  
...  

75 Background: Colorectal cancer is the second leading cause of cancer death in the United States each year. The use of adjuvant chemotherapy after surgical resection of colon cancer has been associated with a survival benefit. Timely initiation of adjuvant chemotherapy has been shown to have an effect on overall and disease-free survival. There is no integrated post-surgical colon cancer care planning for patients who have surgery at our institution. Poor understanding on the part of patients and ancillary providers regarding appropriate follow up may cause delay in time to adjuvant chemotherapy initiation. Methods: Baseline data was obtained for the ASCO Quality Training Program. Chart review was conducted on patients with stage III colorectal cancer that were treated at the Cancer Institute of New Jersey and Robert Wood Johnson University Hospital to identify average time to adjuvant chemotherapy initiation and factors which were thought to have a strong influence on chemotherapy initiation. Time to initiation of adjuvant chemotherapy, pathology report resulting, central access obtainment, and outpatient medical oncology appointment was abstracted from patient charts. Other factors including the presence of intraoperative or postoperative complications, type of surgeon, academic versus private medical oncologist, and the presence of an inpatient medical oncology consult were also identified and reviewed. Results: 128 patient charts were reviewed. Mean number of days from surgery to adjuvant chemotherapy (n = 79) was 49.6, to pathology report resulting (n = 70) was 4.92, to central access obtainment (n = 49) was 40, and to outpatient medical oncology appointment (n = 38) was 30. The presence of intraoperative (p < 0.059) and postoperative complications (p < 0.0155) was found to have a statistically significant effect on time to initiation of adjuvant chemotherapy. Conclusions: While there are some uncontrollable factors like operative complications that delay time to initiation of chemotherapy, engaging the patient may help decrease the time to adjuvant chemotherapy by increasing patient awareness of the importance of seeking aggressive postoperative care.


2016 ◽  
Vol 26 (10) ◽  
pp. 799-805 ◽  
Author(s):  
Yoon Bin Jung ◽  
Jeonghyun Kang ◽  
Eun Jung Park ◽  
Seung Hyuk Baik ◽  
Kang Young Lee

2015 ◽  
Vol 11 (1) ◽  
pp. e28-e35 ◽  
Author(s):  
David W. Wasserman ◽  
Majdi Boulos ◽  
Wilma M. Hopman ◽  
Christopher M. Booth ◽  
Rachel Goodwin ◽  
...  

In patients with no reason for delay, most experienced a delay of > 8 weeks. The authors say this likely reflects delays in referral, consultation, and chemotherapy booking. These health-system factors are modifiable, and future quality improvement initiatives should focus on how to reduce them.


Swiss Surgery ◽  
2003 ◽  
Vol 9 (1) ◽  
pp. 3-7 ◽  
Author(s):  
Gervaz ◽  
Bühler ◽  
Scheiwiller ◽  
Morel

The central hypothesis explored in this paper is that colorectal cancer (CRC) is a heterogeneous disease. The initial clue to this heterogeneity was provided by genetic findings; however, embryological and physiological data had previously been gathered, showing that proximal (in relation to the splenic flexure) and distal parts of the colon represent distinct entities. Molecular biologists have identified two distinct pathways, microsatellite instability (MSI) and chromosomal instability (CIN), which are involved in CRC progression. In summary, there may be not one, but two colons and two types of colorectal carcinogenesis, with distinct clinical outcome. The implications for the clinicians are two-folds; 1) tumors originating from the proximal colon have a better prognosis due to a high percentage of MSI-positive lesions; and 2) location of the neoplasm in reference to the splenic flexure should be documented before group stratification in future trials of adjuvant chemotherapy in patients with stage II and III colon cancer.


Sign in / Sign up

Export Citation Format

Share Document